23:52 , Oct 6, 2017 |  BioCentury  |  Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
16:46 , Aug 4, 2017 |  BC Week In Review  |  Company News

Evotec acquiring Aptuit

Evotec AG (Xetra:EVT) is acquiring fellow drug discovery services company Aptuit LLC (Greenwich, Conn.) for $300 million. Evotec said it would finance the acquisition, which is expected to close in 3Q17, through a €140 million...
22:51 , Jul 31, 2017 |  BC Extra  |  Company News

Evotec acquiring Aptuit

Evotec AG (Xetra:EVT) is acquiring fellow drug discovery services company Aptuit LLC (Greenwich, Conn) for $300 million. Evotec said it would finance the acquisition, which is expected to close in 3Q17, through a €140 million...
19:08 , Mar 23, 2017 |  BC Innovations  |  Finance

Biology on the mind

Less than a year and a half after its launch, the Dementia Discovery Fund has spawned four new companies and invested almost 10% of the roughly $100 million it raised in 2015. With a goal...
16:24 , Mar 17, 2017 |  BC Week In Review  |  Company News

Aptuit, BioVersys deal

Aptuit partnered with BioVersys to discover and validate targets in Gram-negative bacteria. Aptuit will provide in vitro and in vivo discovery services. BioVersys will contribute an undisclosed target to the collaboration. BioVersys declined to provide...
20:31 , Feb 3, 2017 |  BC Week In Review  |  Company News

Aptuit, Massachusetts General Hospital deal

Aptuit partnered with Massachusetts General Hospital to discover and validate targets in Gram-negative bacteria, including Pseudomonas aeruginosa . Aptuit will provide the hospital’s Molecular Surgical Laboratory with in vitro and in vivo discovery services. Aptuit...
07:00 , Sep 12, 2016 |  BioCentury  |  Strategy

Dealing Denali

Denali Therapeutics Inc .'s recent unveiling of 11 deals provides the first glimpse of how the company plans to deploy its nearly $350 million war chest to target neurodegenerative diseases. The company has previously said...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Company News

Aptuit, GlaxoSmithKline deal

CRO Aptuit said it reached an agreement for a "multiyear extension" of its drug development and R&D services partnership with GlaxoSmithKline. The partners could not be reached for details (see BioCentury, July 12, 2010). Aptuit...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Company News

Aptuit, Catalent Pharma deal

Catalent completed its acquisition of Aptuit's clinical trial supplies business (see BioCentury, Aug. 29, 2011). Aptuit LLC , Greenwich, Conn.   Catalent Pharma Solutions Inc. , Somerset, N.J.   Business: Supply/Service  ...
07:00 , Aug 29, 2011 |  BC Week In Review  |  Company News

Aptuit, Catalent Pharma deal

Catalent will acquire Aptuit's clinical trial supplies business for $410 million in cash on a cash and debt free basis. Catalent said the deal will expand its development and clinical services business. The deal is...